Details of the Drug Combinations

General Information of This Drug (ID: DMS104F)

• Drug Name: Temsirolimus (DMS104F)
• Synonyms: Torisel

Indication

Renal cell carcinoma; ICD 11: 2C90; Status: Approved [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

2 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Temsirolimus + Panobinostat	DCI8RK3	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Temsirolimus + Idarubicin	DCLVWKC	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]

25 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Bortezomib + Temsirolimus	DCM5FIW	Bortezomib	Multiple Myeloma	[3]
Bryostatin-1 + Temsirolimus	DCQM188	Bryostatin-1	Recurrent Melanoma	[4]
Cladribine + Temsirolimus	DCNYKD4	Cladribine	Lymphoma	[5]
Dexamethasone + Temsirolimus	DCXRLI0	Dexamethasone	Refractory Multiple Myeloma	[6]
Diphenhydramine + Temsirolimus	DCG8MHZ	Diphenhydramine	Prostate Cancer	[7]
Docetaxel + Temsirolimus	DCSMSTV	Docetaxel	Resistant Solid Malignancies	[8]
Erlotinib + Temsirolimus	DCHJAAP	Erlotinib	Adult Anaplastic Astrocytoma	[9]
HKI-272 + Temsirolimus	DCVRHD0	HKI-272	Breast Cancer	[10]
Irinotecan + Temsirolimus	DCLPX9I	Irinotecan	Metastatic Colorectal Cancer	[11]
Lenalidomide + Temsirolimus	DCNK7LQ	Lenalidomide	Refractory Multiple Myeloma	[12]
Pelitinib + Temsirolimus	DCQIQ6F	Pelitinib	Unspecified Adult Solid Tumor, Protocol Specific	[13]
Pemetrexed + Temsirolimus	DC7KUDQ	Pemetrexed	Carcinoma, Non-Small-Cell Lung	[14]
Selumetinib + Temsirolimus	DCABPQ8	Selumetinib	Breast Cancer	[15]
Selumetinib + Temsirolimus	DCYW8E5	Selumetinib	Mucosal Melanoma	[16]
Sunitinib + Temsirolimus	DCF44X2	Sunitinib	Metastatic Renal Cell Carcinoma	[17]
Temozolomide + Temsirolimus	DC8W5PZ	Temozolomide	Adult Giant Cell Glioblastoma	[18]
Temsirolimus + Vorinostat	DC2E6JA	Vorinostat	Advanced Cancer	[19]
Temsirolimus + Valproic Acid	DCBALU3	Valproic Acid	Brain and Central Nervous System Tumors	[20]
Temsirolimus + Bicalutamide	DCT658G	Bicalutamide	Prostate Cancer	[21]
Temsirolimus + Cediranib	DCUWF06	Cediranib	Endometrial Cancer	[22]
Temsirolimus + Perifosine	DCAF92R	Perifosine	Brain Tumor, Recurrent	[23]
Topotecan + Temsirolimus	DCJGINW	Topotecan	Genital Neoplasms, Female	[24]
Vemurafenib + Temsirolimus	DCFINOO	Vemurafenib	Advanced Cancer	[25]
Vinblastine + Temsirolimus	DC4DCA9	Vinblastine	Recurrent Lymphoma	[26]
HKI-272 + Temsirolimus	DCU2M04	HKI-272	HER2-mutant Non-Small Cell Lung Cancer	[27]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5892).
• [2] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [3] ClinicalTrials.gov (NCT00483262) Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma
• [4] ClinicalTrials.gov (NCT00112476) Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
• [5] ClinicalTrials.gov (NCT00787969) Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
• [6] ClinicalTrials.gov (NCT00693433) Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
• [7] ClinicalTrials.gov (NCT00887640) Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
• [8] ClinicalTrials.gov (NCT00703625) Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
• [9] ClinicalTrials.gov (NCT00112736) Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
• [10] ClinicalTrials.gov (NCT01111825) Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer
• [11] ClinicalTrials.gov (NCT00827684) Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations
• [12] ClinicalTrials.gov (NCT00398515) Lenalidomide and Temsirolimus in Treating Patients With Previously Treated Multiple Myeloma
• [13] ClinicalTrials.gov (NCT00098501) CCI-779 and EKB-569 in Treating Patients With Advanced Solid Tumors
• [14] ClinicalTrials.gov (NCT00921310) Temsirolimus and Pemetrexed for Recurrent or Refractory Non-Small Cell Lung Cancer
• [15] ClinicalTrials.gov (NCT00600496) A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• [16] ClinicalTrials.gov (NCT01166126) Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
• [17] ClinicalTrials.gov (NCT01517243) Phase II Study of Alternating Sunitinib and Temsirolimus
• [18] ClinicalTrials.gov (NCT00316849) Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
• [19] ClinicalTrials.gov (NCT01087554) Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
• [20] ClinicalTrials.gov (NCT01204450) Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
• [21] ClinicalTrials.gov (NCT01020305) Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
• [22] ClinicalTrials.gov (NCT01065662) AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
• [23] ClinicalTrials.gov (NCT02238496) Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
• [24] ClinicalTrials.gov (NCT00523432) A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
• [25] ClinicalTrials.gov (NCT01596140) Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
• [26] ClinicalTrials.gov (NCT02343718) Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
• [27] ClinicalTrials.gov (NCT01827267) Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer